Is Ki67 still a powerful ally in predicting the clinical benefit of anthracyclines for the adjuvant treatment of early breast cancer?

Breast Cancer Res Treat. 2018 Apr;168(3):767-768. doi: 10.1007/s10549-017-4630-9. Epub 2018 Jan 6.

Authors

Sara Bravaccini¹, Andrea Rocca², Giuseppe Bronte²

Affiliations

¹ Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Via P. Maroncelli 40, 47014, Meldola (FC), Italy. [email protected].
² Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Via P. Maroncelli 40, 47014, Meldola (FC), Italy.

PMID: 29307047
DOI: 10.1007/s10549-017-4630-9

No abstract available

Publication types

Letter

MeSH terms

Anthracyclines / therapeutic use*
Antineoplastic Combined Chemotherapy Protocols / therapeutic use
Biomarkers, Tumor*
Breast Neoplasms / drug therapy*
Breast Neoplasms / metabolism*
Breast Neoplasms / mortality
Chemotherapy, Adjuvant
Female
Humans
Ki-67 Antigen / metabolism*
Prognosis
Proportional Hazards Models
Treatment Outcome

Substances

Anthracyclines
Biomarkers, Tumor
Ki-67 Antigen